MMWR Morb Mortal Wkly Rep. 2023 Jul 28;72(30):827-832. doi: 10.15585/mmwr.mm7230a4.
In August 2022, the Food and Drug Administration authorized JYNNEOS vaccine (modified vaccinia Ankara vaccine, Bavarian Nordic), a 2-dose series used for the prevention of Monkeypox virus infection, to be administered via a dose-sparing intradermal route, in addition to the previously authorized subcutaneous route. The California Department of Public Health investigated whether demographic disparities in vaccination series completion varied by route of administration of the recipient's first dose. Among California residents who received their first dose during August 9, 2022-March 31, 2023, a total of 59.8% received a second dose. Series completion was highest among non-Hispanic White persons (64.1%), persons aged ≥65 years (72.6%), and adults with male sex assignment at birth (62.1%); series completion was lowest among non-Hispanic Black or African American persons (51.3%), persons aged 18-24 years (42.9%), and adults assigned female sex at birth (42.8%). When the first dose was received by subcutaneous administration, overall series completion was 58.8% compared with 60.2% when the first dose was administered intradermally. Odds of series completion across all race and ethnicity groups, persons aged 18-64 years, community health conditions, and persons assigned male sex at birth were not greater when the first dose was administered subcutaneously compared with intradermally. Intradermal use of JYNNEOS vaccine did not lower overall 2-dose series completion rates. Continued efforts are needed to ensure persons at risk for Monkeypox virus infection receive both recommended doses.
2022 年 8 月，美国食品和药物管理局授权 JYNNEOS 疫苗（改良安卡拉痘苗病毒疫苗，巴伐利亚北欧公司），一种两剂系列疫苗，用于预防猴痘病毒感染，可通过剂量节约的皮内途径给药，除了之前授权的皮下途径。加利福尼亚州公共卫生部调查了受种者首剂接种途径的不同是否导致疫苗接种系列完成情况存在差异。在 2022 年 8 月 9 日至 2023 年 3 月 31 日期间，在加利福尼亚州居住的居民中，共有 59.8%的人接受了第二剂。非西班牙裔白人（64.1%）、年龄≥65 岁（72.6%）和出生时为男性的成年人（62.1%）完成系列接种的比例最高；非西班牙裔黑人或非洲裔美国人（51.3%）、年龄在 18-24 岁的人群（42.9%）和出生时被分配女性性别的成年人（42.8%）完成系列接种的比例最低。当首剂通过皮下给药时，总体系列完成率为 58.8%，而当首剂皮内给药时，总体系列完成率为 60.2%。在所有种族和族裔群体、18-64 岁人群、社区健康状况和出生时被分配男性性别的人群中，与皮内给药相比，当首剂通过皮下给药时，完成系列接种的几率并没有增加。JYNNEOS 疫苗的皮内使用并未降低两剂系列的总体完成率。需要继续努力，确保有感染猴痘病毒风险的人群接种两剂推荐剂量。
